Publications by authors named "Dana Clanton"
Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as a potential treatment for follicular NHL. We have recently reported that galiximab signals B-NHL cells in vitro and inhibits cell growth and sensitizes resistant tumor cells to apoptosis by chemotherapeutic drugs. This study was designed to validate the in vitro findings in in vivo in mice.
View Article and Find Full Text PDFArticle Synopsis
- Colon cancer likely originates from normal colon stem cells, with CD44 identified as a marker for colon cancer stem cells similar to its role in breast and prostate cancer.
- CD44(hi) colon tumor cells showed significantly greater tumorigenic potential in mouse models, forming tumors with much fewer cells compared to CD44(-) cells, indicating a strong self-renewal capacity.
- CD44(hi) cells also displayed characteristics of slow division and were enriched for key nuclear markers related to tumor progression, suggesting further research is needed to enhance the identification and isolation of colon cancer stem cells.